Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma

Summary

This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM. This study will recruit up to 18 patients whose MPM has progressed beyond first-line of palliative chemotherapy, with a platinum-based doublet, and now requires further palliative systemic treatment, or have declined first-line palliative chemotherapy, however must have been considered suitable for a platinum doublet chemotherapy.

Timeline

Start

2021-02-12

Primary completion

2023-07-25

Completion

2023-07-25

Outcome

Outcome not reported

Stopped (Enrollment): “Study terminated due to slow recruitment and insufficient further funding.”

Drugs

Indications